Protherics PLC Announces Research Update
Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, announces that AstraZeneca has treated the first patient in its expanded phase 2 programme of CytoFabTM in severe sepsis, an inflammatory condition resulting from uncontrolled infections. Protherics previously reported encouraging phase 2b study results in an 81 patient study in severe sepsis.
More: continued here
Filed under: Infectious Diseases / Bacteria / Viruses on January 29th, 2008